NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Ascendis Pharma A/S (ASND) Stock Analysis

Ascendis Pharma A/S (ASND) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ASND

$270.56

−$0.56 (−0.21%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ASND with… →

ASND Key Statistics

As of Sep 4, 2026
Trading
Open
$267.96
Previous Close
$271.12
Day's Range
265.22–271.14
52-Week Range
186.05–282.15
Volume
723.50K
Valuation
Market Cap
$17.75B
P/E Ratio
20.92
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
29.02
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
16.95
EPS (ttm)Profit attributable to each share over the last twelve months.
12.93
Financials (FY)
Revenue (FY)
$720.13M+98.03%
Net Income (FY)
−$228.03M
Profit marginThe share of revenue left as profit after all costs and taxes.
70.84%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
65.59M
1-Year Return
+36.56%
Dividend and dates
Avg Volume
665.27K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ASND Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+26.88%
2025+54.89%
2024+9.31%
2023+3.13%
2022−9.22%
2021−19.34%
2020+19.88%
2019+122.06%
2018+56.39%
2017+97.92%
2016 (partial year)+40.56%

As of September 4, 2026.

ASND Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$720.13M−$228.03M−31.7%
2024$363.64M−$378.08M−104.0%
2023$266.72M−$481.45M−180.5%
2022$51.17M−$583.19M−1139.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$720.13M$625.22M−$136.27M−$228.03M−31.7%
2024$363.64M$319.38M−$278.76M−$378.08M−104.0%
2023$266.72M$222.32M−$455.54M−$481.45M−180.5%
2022$51.17M$39.04M−$561.81M−$583.19M−1139.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ASND Valuation vs Biotechnology Median

Median of 656 stocks
MetricASNDBiotechnology medianvs median
P/E20.9212.5766% above
P/S ratio16.9515.2611% above
Profit margin70.84%0.00%70.8 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Ascendis Pharma A/S (ASND) carries a market capitalisation of $17.75B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 1,189 employees.

The 52-week range on file runs from $186.05 to $282.15. ASND last closed at $270.56 on September 4, 2026. That is −$0.56 (−0.21%) against the previous close. The latest close sits 45.42% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $720.13M. That is +98.03% against the prior fiscal year, when revenue was $363.64M. The same year closed with a net loss of $228.03M. The reported profit margin is 70.85%. That is 70.8 percentage points above the Biotechnology median of 0%. Earnings per share on a trailing basis come to 12.93.

Across the 4 fiscal years on file, revenue moves from $51.17M in 2022 to $720.13M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 20.92 times earnings. That is 66.43% above the Biotechnology median of 12.57. On forward earnings the ratio is 29.02. Measured against sales, the shares trade at 16.95 times revenue. On price-to-sales that is 11.05% above the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is +36.56%. Measured over 10 years, that is +30.15% a year compounded. Daily returns over the trailing 10 years annualize to a volatility of 50.81%.

Growth & Income

The record shows no dividend for ASND.

So far in 2026 the price is +26.88%. Across the complete calendar years on file, 2019 returned +122.06% and 2021 returned −19.34%. Of the 9 complete calendar years on file, 7 finished higher.

Peer Comparison

Ascendis Pharma A/S (ASND) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Ascendis Pharma A/S ASND $17.75B 20.9
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Ascendis Pharma A/S trades at a P/E of 20.9.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Ascendis Pharma A/S

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Visit website →